Wegovy, an anti-obesity drug from Novo Nordisk, is now available in France, but the government is cautious about its endorsement. The drug costs between €270 and €330 monthly, and patients must pay out-of-pocket as it is not covered by national health insurance. Experts warn that Wegovy is not a miracle solution and should be prescribed carefully. Other countries, including Germany and the UK, have similar restrictions. The drug is also available in several other countries, with ongoing discussions about its long-term effects and accessibility. Teljes cikk (Euronews.com)